<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997334</url>
  </required_header>
  <id_info>
    <org_study_id>09-210</org_study_id>
    <secondary_id>NE_OSI4590s</secondary_id>
    <nct_id>NCT00997334</nct_id>
  </id_info>
  <brief_title>Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC</brief_title>
  <official_title>First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David M. Jackman, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erlotinib is a drug which targets non small cell lung cancer with a genetic change (mutation)
      in the epidermal growth factor receptor (EGFR). This drug has been used in other cancer
      research studies and information from those studies suggests that Erlotinib can control the
      growth of these cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE

      -To prospectively assess the frequency of different genetic mechanisms of secondary
      resistance in patients' tumors during treatment with erlotinib (e.g., T790M mutations, MET
      amplification).

        -  Correlate these genetic changes with patient demographic data and clinical outcomes
           (time to progression, survival, sites of recurrence/progression).

        -  Search for novel mechanisms of acquired resistance to erlotinib.

        -  Identify whether these genetic changes are present at low levels in initial pretreatment
           tumor specimens.

      SECONDARY OBJECTIVE(S)

        1. To measure the steady-state plasma concentrations of erlotinib during the course of
           patients' treatment.

             -  Determine if the development and/or resolution of skin toxicity is related to
                plasma erlotinib concentrations.

             -  Determine if the development of disease progression while on erlotinib is
                correlated with declines in plasma erlotinib concentrations.

             -  Assess the plasma levels in patients whose smoking status has been biochemically
                verified to determine if smoking is associated with lower erlotinib plasma
                concentration.

        2. To analyze from both free plasma DNA and DNA from circulating tumor cells of
           erlotinib-treated patients for the original sensitizing EGFR mutations and genetic
           changes associated with secondary resistance.

        3. To measure clinical outcomes in patients with known sensitizing mutations in their tumor
           EGFR when treated with first-line erlotinib.

             -  Response rate

             -  Time to progression

             -  Median overall survival
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resistance Mechanism</measure>
    <time_frame>Participants were evaluated for incidence of genetic mechanisms of secondary resistance at time of disease progression at which point participants stopped treatment. Progression follow up was up to 3 years in this study cohort.</time_frame>
    <description>Participants were classified into 4 potential resistant mechanism groups (4 genetic/ 1 histologic) based on evaluation of rebiopsy tissue: EGFR mutations (T790M mutation, exon 20 insertion), KRAS mutations, MET amplification or small-cell lung cancer (SCLC) transform using established methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Disease was evaluated radiologically every 8 weeks on treatment (cycle duration=4 weeks). Participants were treated until evidence of disease progression or unacceptable toxicity. Progression follow-up was up to 3 years in this study cohort.</time_frame>
    <description>Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer, stage IV or IIIB
             with a malignant pleural or pericardial effusion. Patients with stage I or II
             non-small cell lung cancer who have undergone surgical resection but who subsequently
             relapse with metastatic disease or a malignant pleural effusion are also eligible.

          -  Documentation of a sensitizing mutation of the epidermal growth factor receptor. In
             addition, there must be a sufficient tissue for analysis of KRAS (the oncogene from
             the Kirsten rat sarcoma virus) mutations and MET amplification.

          -  At least one measurable or evaluable site of disease as defined by revised RECIST
             (version 1.1) criteria.

          -  18 years of age or older

          -  No more than one prior systemic therapy regimen for advanced non-small cell lung
             cancer. Chemotherapy delivered as part of concurrent chemoradiation will also count as
             a prior systemic therapy regimen. Adjuvant therapy for resected NSCLC will not count
             towards this total as long as it was completed at least 6 months prior to enrollment
             and did not include therapy with an EGFR-targeted agent. Adjuvant therapy completed
             less than 6 months prior to the time of screening will count as a prior regimen.

          -  3 or more weeks since prior major surgery

          -  2 or more weeks since prior radiation

          -  ECOG performance status 0-1

          -  Life expectancy &gt; 8 weeks

          -  Adequate hematologic, renal, and hepatic function

          -  Willingness to undergo repeat tumor biopsy at the time of disease progression.

        Exclusion Criteria:

          -  Untreated and/or uncontrolled central nervous system metastases. Patients with prior
             brain metastases must have had definitive treatment (radiation or surgery) and must be
             clinically stable off steroids for at least 1 week prior to enrollment.

          -  More than one prior systemic chemotherapy for advanced non-small cell lung cancer. ,
             Chemotherapy delivered as part of concurrent chemoradiation will also count as a prior
             systemic therapy regimen. Adjuvant therapy for resected NSCLC willnot count towards
             this total as long as it was completed at least 6 months prior to enrollment and did
             not include therapy with an EGFR-targeted agent. Adjuvant therapy completed less than
             6 months prior to the time of screening will count as a prior regimen.

          -  Prior exposure to erlotinib or other treatments targeting the HER family axis.

          -  Active malignancies within the past 3 years, except for adequately treated carcinoma
             of the cervix or basal or squamous cell carcinomas of the skin.

          -  Any process that compromises the ability to swallow and/or absorb oral medication.

          -  Incomplete healing from previous surgery

          -  A history of any of the following autoimmune skin disorders: Sjogren's syndrome,
             scleroderma, dermatomyositis, and systemic lupus erythematosus.

          -  Significant medical history or unstable medical conditions.

          -  Concurrent use of warfarin. Patients must be off warfarin for at least one week prior
             to initiation of erlotinib. Other non-warfarin anticoagulants are permitted.

          -  Patients who require ongoing concomitant use of one of the strong inhibitors/inducers
             of CYP3A4.

          -  Pregnant or breastfeeding. Women of child-bearing potential must agree to use adequate
             contraception prior to study entry and for the duration of study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jackman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://oncology.jamanetwork.com/article.aspx?articleid=2532348</url>
  </link>
  <results_reference>
    <citation>Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA Oncol. 2016 Sep 1;2(9):1240-2. doi: 10.1001/jamaoncol.2016.1304.</citation>
    <PMID>27387964</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <results_first_submitted>January 5, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2017</results_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>David M. Jackman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <keyword>EGFR mutation</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study activated December 2009. Patients enrolled from February 2010 - January 2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib</title>
          <description>Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible for Repeat Biopsy</title>
              <participants_list>
                <participants group_id="P1" count="44">Patients who experience disease progression on treatment were eligible for repeat biopsy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable</title>
              <participants_list>
                <participants group_id="P1" count="35">Patients with tissue available for re-biopsy at time of progression</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>still on therapy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Urgent Palliative Care</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No lesion amenable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis data is comprised of all treated patients</population>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib</title>
          <description>Patients receive standard dose of erlotinib 150mg daily with cycle length of 28 days; Patients are treated until disease progression or until unaccepted drug toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="34" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never-Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Resistance Mechanism</title>
        <description>Participants were classified into 4 potential resistant mechanism groups (4 genetic/ 1 histologic) based on evaluation of rebiopsy tissue: EGFR mutations (T790M mutation, exon 20 insertion), KRAS mutations, MET amplification or small-cell lung cancer (SCLC) transform using established methods.</description>
        <time_frame>Participants were evaluated for incidence of genetic mechanisms of secondary resistance at time of disease progression at which point participants stopped treatment. Progression follow up was up to 3 years in this study cohort.</time_frame>
        <population>The analysis dataset is comprised of all evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib</title>
            <description>Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Resistance Mechanism</title>
          <description>Participants were classified into 4 potential resistant mechanism groups (4 genetic/ 1 histologic) based on evaluation of rebiopsy tissue: EGFR mutations (T790M mutation, exon 20 insertion), KRAS mutations, MET amplification or small-cell lung cancer (SCLC) transform using established methods.</description>
          <population>The analysis dataset is comprised of all evaluable patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T790M mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MET amplification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCLC Transformation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insufficient Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.</description>
        <time_frame>Disease was evaluated radiologically every 8 weeks on treatment (cycle duration=4 weeks). Participants were treated until evidence of disease progression or unacceptable toxicity. Progression follow-up was up to 3 years in this study cohort.</time_frame>
        <population>The analysis dataset is comprised of all treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib</title>
            <description>Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.</description>
          <population>The analysis dataset is comprised of all treated patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="9.1" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Time to Repeat Biopsy</title>
        <description>Time to repeat biopsy is the duration of time from clinical determination of progressive disease to time of repeat biopsy.</description>
        <time_frame>At time of removal from study, patients were asked to undergo a repeat biopsy of their progressing or new tumor lesion. Progression follow up was up to 3 years in this study cohort.</time_frame>
        <population>The analysis dataset is comprised of all evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib</title>
            <description>Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Repeat Biopsy</title>
          <description>Time to repeat biopsy is the duration of time from clinical determination of progressive disease to time of repeat biopsy.</description>
          <population>The analysis dataset is comprised of all evaluable patients.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="0" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Feasibility Rate</title>
        <description>Feasibility in this study is defined as the percentage of patients who completed a repeated biopsy per protocol after evidence of disease progression.</description>
        <time_frame>Disease was evaluated radiologically every 8 weeks on treatment (cycle duration=4 weeks). Participants were treated until evidence of disease progression or unacceptable toxicity. Progression follow-up was up to 3 years in this study cohort.</time_frame>
        <population>The analysis dataset is comprised of all patients eligible for repeat biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib</title>
            <description>Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Rate</title>
          <description>Feasibility in this study is defined as the percentage of patients who completed a repeated biopsy per protocol after evidence of disease progression.</description>
          <population>The analysis dataset is comprised of all patients eligible for repeat biopsy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="67.0" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed each cycle on treatment up to day 30 post-treatment. Median (range) treatment duration for this study cohort was 10 months (1-62 months).</time_frame>
      <desc>Serious adverse events (AEs) per protocol are reported. For Other AEs, maximum grade toxicity by type (based on CTCAEv3 which includes coding events as ‘Other') for a patient over time including only events with treatment-attribution of possibly, probably or definitely was calculated. A patient appears only once for a given type of toxicity. Patients with reports of multiple toxicities of different types are reported multiple times under the relevant toxicity categories.</desc>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib</title>
          <description>Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac - ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac General-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ulcer, colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death - Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Eyelid dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ocular-other</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Distention/bloating, abdominal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper GI, hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdomen, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oral cavity, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Syndromes-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut, conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, ungual</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC mucosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC oral cavity/gums</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC ungual (nails)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, ungual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC vagina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity-limb, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Joint, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathy CN IX pharynx ear tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathy CN XII tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathic, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nose, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Scalp, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vascular-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David M. Jackman, MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617.632.3468</phone>
      <email>David_Jackman@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

